Analyst Price Target is $8.00
▲ +146.15% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for ASLAN Pharmaceuticals in the last 3 months. The average price target is $8.00, with a high forecast of $8.00 and a low forecast of $8.00. The average price target represents a 146.15% upside from the last price of $3.25.
Current Consensus is
The current consensus among 2 contributing investment analysts is to buy stock in ASLAN Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Aslan Pharmaceuticals Ltd. is a clinical-stage oncology-focused biopharmaceutical company, which engages in the development of novel therapeutics. It focuses on atopic dermatitis, other immunology indications and autoimmune disease. Its pipeline includes varlitinib, ASLAN003, ASLAN004, and AhR Antagonist. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale, and Jeffrey Tomlinson in 2010 and is headquartered in Singapore.